Implementing ICH Q9 for GMP quality risk management compliance

In the ever-evolving pharmaceutical landscape, quality risk management is crucial in ensuring product safety and efficacy, with a primary focus on patient protection. In this context, the ICH Q9 standard, developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), is a fundamental guide for implementing an effective quality risk management (QRM) system. The ICH guidelines provide a framework for risk management in pharma, outlining key quality risk management principles.

What is ICH Q9?

ICH Q9 is not simply a manual or a list of tools but a framework that provides a common language and a structured process for quality risk management in the pharmaceutical industry, particularly for drug substances, drug products, biological products and biotechnological products. This standard was developed to promote a shared understanding of QRM between the pharmaceutical industry and regulatory authorities like the FDA, facilitating communication, efficiency and transparency.

Fulfilling GMP compliance requirements

In Good Manufacturing Practice (GMP) audits, it states clearly that a company must employ robust risk analysis and management as one fulfillment criteria. The ICH Q9 guidelines, developed with sets of methodologies and tools, are designed for pharmaceutical companies to adopt and demonstrate good quality risk management practices in place throughout the product life cycle, from development and manufacturing to validation and ongoing quality updates.

Why is ICH Q9 important?

Implementing the Q9 quality risk management standard offers numerous advantages for the pharmaceutical industry:

Patient Focus: ICH Q9 emphasizes basing risk assessment on sound scientific knowledge, with the ultimate goal of protecting the patient.
Science-Based Decisions: It promotes a scientific and data-driven approach to risk evaluation, reducing subjectivity in decision-making.
Efficient Use of Resources: Identifying and managing risk priorities allows for optimal use of available resources in development, manufacturing, validation and qualification activities.
Continuous Improvement: Reducing or removing barriers to continuous improvement enables increased production efficiency and maintaining or enhancing pharmaceutical quality.
Trust with Regulatory Authorities: Building trust with regulatory authorities is facilitated by transparency and open communication around the quality and risk management system.

QRM process according to ICH Q9

ICH Q9 outlines a structured QRM process with four main phases:

Risk Assessment: Identifying potential risks, analyzing their probability, severity, and detectability, and risk ranking. This includes risk identification for critical quality attributes and critical process parameters.
Risk Control: Assessing risk acceptance and implementing control strategies and risk mitigation to reduce risks to an acceptable level.
Risk Communication: Effectively communicating risks and control strategies to all stakeholders.
Risk Review: Continuously monitoring and reviewing the results of the QRM process, considering new knowledge and experiences.

Tools and methodologies for QRM in ICH Q9

ICH Q9 does not prescribe specific methodologies for QRM but suggests various tools that can be used, providing quality risk management examples such as:

FMEA (Failure Modes and Effects Analysis): An inductive method that assesses the effects of a potential failure mode on the system.
FTA (Fault Tree Analysis): A deductive method used to identify the causal chain leading to an undesirable event.
HAZOP (Hazard and Operability Study): An inductive method that identifies potential deviations from the initial design of a system.
HACCP (Hazard Analysis and Critical Control Points): An inductive method used to identify and control critical points in a process.

Implementing a quality risk management system according to the ICH Q9 standard represents a fundamental step for the pharmaceutical industry towards safety and quality commitments to consumers. It also facilitates compliance to GMP audits in a systematic and traceable manner, supporting a risk-based approach to process robustness.

If you are looking for support in setting up your own QRM systems, you can talk to our teams who have extensive experience and expertise in the field, making us the ideal partner for you on this.

Eurofins Assurance

Eurofins Consumer Products Assurance

Eurofins Food Assurance

Eurofins Healthcare Assurance